Psilocybin Therapy for Clinicians With Symptoms of Depression From Frontline Care During the COVID-19 Pandemic
JAMA Network Open December 5, 2024 Anthony L Back, Timara K Freeman-Young, Ladybird Morgan et al. 37 citations
A double-blind randomized trial tested psilocybin therapy against niacin in 30 US clinicians (physicians, advanced practice practitioners, and nurses) who developed depression, burnout, or PTSD from frontline COVID-19 pandemic work. Participants had no prepandemic mental health diagnoses but had moderate or severe depression at enrollment. After one medication session, depression symptoms (measured by the Montgomery-Asberg Depression Rating Scale) improved significantly more with psilocybin (mean decrease of 21.33 points) than with niacin (mean decrease of 9.33 points), a difference of 12.00 points. Burnout and PTSD symptoms showed numerically larger improvements with psilocybin, but these differences were not statistically significant. The findings suggest psilocybin therapy can reduce depression in this postpandemic condition.